Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Receptor, ErbB-2"" wg kryterium: Temat


Tytuł :
Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer.
Autorzy :
Takahashi R; Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Koto-ku, AriakeTokyo, 135-8550, Japan.
Nunobe S; Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Koto-ku, AriakeTokyo, 135-8550, Japan. .
Osumi H; Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Takahari D; Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yamamoto N; Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ida S; Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Koto-ku, AriakeTokyo, 135-8550, Japan.
Kumagai K; Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Koto-ku, AriakeTokyo, 135-8550, Japan.
Ohashi M; Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Koto-ku, AriakeTokyo, 135-8550, Japan.
Sano T; Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31Koto-ku, AriakeTokyo, 135-8550, Japan.
Hiki N; Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
Pokaż więcej
Źródło :
Surgery today [Surg Today] 2020 Oct; Vol. 50 (10), pp. 1240-1248. Date of Electronic Publication: 2020 May 26.
Typ publikacji :
Journal Article
MeSH Terms :
Esophagogastric Junction*
Gastrectomy*
Receptor, ErbB-2*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Esophageal Neoplasms/*drug therapy
Esophageal Neoplasms/*surgery
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*surgery
Trastuzumab/*administration & dosage
Adult ; Aged ; Combined Modality Therapy ; Coronavirus Infections/drug therapy ; Disease-Free Survival ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/pathology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Preoperative Care ; Retrospective Studies ; Stomach Neoplasms/genetics ; Stomach Neoplasms/pathology ; Young Adult
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Autorzy :
Li A; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Bai Q; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Kong H; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Zhou S; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Lv H; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Zhong S; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Li M; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Bi R; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Zhou X; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Yang W; From the Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Institute of Pathology, Fudan University, Shanghai, China.
Pokaż więcej
Źródło :
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2020 Sep 01; Vol. 144 (9), pp. 1097-1107.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms/*metabolism
Receptor, ErbB-2/*metabolism
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Male ; Middle Aged ; Practice Guidelines as Topic ; Receptor, ErbB-2/genetics ; Young Adult
Czasopismo naukowe
Tytuł :
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
Autorzy :
Stravodimou A; Division of Medical Oncology, Centre Hospitalier Universiitaire Vaudois, Lausanne, Switzerland.
Voutsadakis IA; Algoma District Cancer Program, Sault Area Hospital, Sault Ste Marie, ON, Canada .; Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Sep; Vol. 40 (9), pp. 4829-4841.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*drug therapy
Receptor, ErbB-2/*metabolism
Receptors, Estrogen/*metabolism
Apoptosis/drug effects ; Breast Neoplasms/pathology ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Female ; Humans ; Mutation ; Phosphatidylinositol 3-Kinases/metabolism ; Receptor, ErbB-2/antagonists & inhibitors ; Receptors, Estrogen/antagonists & inhibitors ; Receptors, Estrogen/genetics ; Receptors, Fibroblast Growth Factor/antagonists & inhibitors ; Receptors, Fibroblast Growth Factor/metabolism ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.
Autorzy :
Dieci MV; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy. Electronic address: .
Miglietta F; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Griguolo G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
Pokaż więcej
Źródło :
Cancer treatment reviews [Cancer Treat Rev] 2020 Aug; Vol. 88, pp. 102064. Date of Electronic Publication: 2020 Jun 24.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Breast Neoplasms/*metabolism
Receptor, ErbB-2/*metabolism
Receptors, Cell Surface/*metabolism
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/biosynthesis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Female ; Humans ; Neoplasm Metastasis ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/biosynthesis ; Receptor, ErbB-2/genetics ; Receptor, ErbB-3/biosynthesis ; Receptor, ErbB-3/genetics ; Receptor, ErbB-3/metabolism
Czasopismo naukowe
Tytuł :
Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
Autorzy :
Zervantonakis IK; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15213; .; UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15232.; Department of Cell Biology, Harvard Medical School, Boston, MA 02115.
Poskus MD; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15213.
Scott AL; Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15213.
Selfors LM; Department of Cell Biology, Harvard Medical School, Boston, MA 02115.
Lin JR; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115.
Dillon DA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115.
Pathania S; Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125.
Sorger PK; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115.
Mills GB; Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR 97239.
Brugge JS; Department of Cell Biology, Harvard Medical School, Boston, MA 02115; .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Jul 14; Vol. 117 (28), pp. 16500-16508. Date of Electronic Publication: 2020 Jun 29.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antineoplastic Agents/*pharmacology
Breast Neoplasms/*metabolism
Fibroblasts/*drug effects
Protein Kinase Inhibitors/*pharmacology
Receptor, ErbB-2/*antagonists & inhibitors
TOR Serine-Threonine Kinases/*metabolism
Apoptosis/drug effects ; Breast Neoplasms/genetics ; Breast Neoplasms/physiopathology ; Cell Line, Tumor ; Female ; Fibroblasts/cytology ; Fibroblasts/enzymology ; Humans ; Lapatinib/pharmacology ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Signal Transduction/drug effects ; TOR Serine-Threonine Kinases/genetics
Czasopismo naukowe
Tytuł :
The force of HER2 - A druggable target in NSCLC?
Autorzy :
Jebbink M; Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: .
de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: .
Boelens MC; Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: .
Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: .
Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Cancer treatment reviews [Cancer Treat Rev] 2020 Jun; Vol. 86, pp. 101996. Date of Electronic Publication: 2020 Feb 28.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*enzymology
Lung Neoplasms/*drug therapy
Lung Neoplasms/*enzymology
Receptor, ErbB-2/*genetics
Animals ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Carcinoma, Non-Small-Cell Lung/genetics ; Gene Amplification ; Humans ; Immunoconjugates/immunology ; Immunoconjugates/therapeutic use ; Lung Neoplasms/genetics ; Molecular Targeted Therapy ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/biosynthesis ; Receptor, ErbB-2/immunology
Czasopismo naukowe
Tytuł :
An ErbB2 splice variant lacking exon 16 drives lung carcinoma.
Autorzy :
Smith HW; Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; .
Yang L; Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.; Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.
Ling C; Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.
Walsh A; Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.; Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.
Martinez VD; Department of Integrative Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
Boucher J; Institute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
Zuo D; Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.
Sokol ES; Foundation Medicine, Boston, MA 02141.
Pavlick DC; Foundation Medicine, Boston, MA 02141.
Frampton GM; Foundation Medicine, Boston, MA 02141.
Chmielecki J; Translational Medicine and Oncology, AstraZeneca, Waltham, MA 02451.
Jones LM; Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada.; Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.; Moleculight, Toronto, ON M5G 1T6, Canada.
Roux PP; Institute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
Lockwood WW; Department of Integrative Oncology, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
Muller WJ; Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada; .; Department of Biochemistry, McGill University, Montréal, QC H3A 1A3, Canada.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Aug 18; Vol. 117 (33), pp. 20139-20148. Date of Electronic Publication: 2020 Jul 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genetic Predisposition to Disease*
Carcinoma/*genetics
Lung Neoplasms/*genetics
Protein Isoforms/*genetics
Receptor, ErbB-2/*metabolism
Animals ; Cell Line, Tumor ; Female ; Humans ; Male ; Mice ; Rats ; Receptor, ErbB-2/genetics ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
[Key points of diagnosis and treatment for HER2 positive breast cancer].
Autorzy :
Xu FR; Department of Breast Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100070, China.
Jiang ZF; Department of Breast Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100070, China.
Pokaż więcej
Źródło :
Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2020 Aug 11; Vol. 100 (30), pp. 2324-2327.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms*
Receptor, ErbB-2*
Trastuzumab
Czasopismo naukowe
Tytuł :
Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab'-Immunoliposomes for Gene Silencing in Breast Cancer Cells.
Autorzy :
Khan A; Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia.
Aljarbou AN; Department of Pharmaceutics, College of Pharmacy, Qassim University, Al-Qassim, Buraydah, Saudi Arabia.
Aldebasi YH; Department of Optometry, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia.
Allemailem KS; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia.
Alsahli MA; Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia.
Khan S; Dentistry and Pharmacy College, Buraydah Private Colleges, Al-Qassim, Buraydah, Saudi Arabia.
Alruwetei AM; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia.
Khan MA; Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Al-Qassim, Buraydah, Saudi Arabia.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2020 Aug 05; Vol. 15, pp. 5575-5589. Date of Electronic Publication: 2020 Aug 05 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms/*genetics
Fatty Acid Synthase, Type I/*genetics
Molecular Targeted Therapy/*methods
Receptor, ErbB-2/*metabolism
Breast Neoplasms/therapy ; Cell Line, Tumor ; Cell Survival/genetics ; Female ; Gene Silencing ; Humans ; Hydrogen-Ion Concentration ; Immunoglobulin Fab Fragments/chemistry ; Lipids/chemistry ; Liposomes/administration & dosage ; Liposomes/chemistry ; Liposomes/immunology ; MCF-7 Cells ; RNA, Small Interfering/genetics ; Receptor, ErbB-2/immunology
Czasopismo naukowe
Tytuł :
The loss of nuclear expression of single-stranded DNA binding protein 2 of gastric adenocarcinoma and its prognostic role: Analysis of molecular subtype.
Autorzy :
Bang S; Departments of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Kim H; Departments of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Jang K; Departments of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Paik SS; Departments of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Shin SJ; Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Aug 03; Vol. 15 (8), pp. e0236896. Date of Electronic Publication: 2020 Aug 03 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Stomach Neoplasms*/classification
Stomach Neoplasms*/pathology
DNA-Binding Proteins/*metabolism
Receptor, ErbB-2/*genetics
Adenocarcinoma/pathology ; Aged ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Nucleus/metabolism ; DNA-Binding Proteins/genetics ; Female ; Gene Expression ; Herpesvirus 4, Human/isolation & purification ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prognosis ; Receptor, ErbB-2/metabolism ; Transcription Factors/genetics ; Transcription Factors/metabolism
Czasopismo naukowe
Tytuł :
Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.
Autorzy :
Sandén E; Department of Clinical Sciences in Lund, Oncology and Pathology, Faculty of Medicine, Lund University Cancer Center / Kamprad, Lund University and Skåne University Hospital, Lund, Sweden.
Khazaei S; Department of Clinical Sciences in Lund, Oncology and Pathology, Faculty of Medicine, Lund University Cancer Center / Kamprad, Lund University and Skåne University Hospital, Lund, Sweden.
Tryggvadottir H; Department of Clinical Sciences in Lund, Oncology and Pathology, Faculty of Medicine, Lund University Cancer Center / Kamprad, Lund University and Skåne University Hospital, Lund, Sweden.
Borgquist S; Department of Clinical Sciences in Lund, Oncology and Pathology, Faculty of Medicine, Lund University Cancer Center / Kamprad, Lund University and Skåne University Hospital, Lund, Sweden.; Departments of Oncology and Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Isaksson K; Department of Clinical Sciences in Lund, Surgery, Faculty of Medicine, Lund University Cancer Center, Lund University and Skåne University Hospital, Lund, Sweden, and Central Hospital Kristianstad, Kristianstad, Sweden.
Jirström K; Department of Clinical Sciences in Lund, Oncology and Pathology, Faculty of Medicine, Lund University Cancer Center / Kamprad, Lund University and Skåne University Hospital, Lund, Sweden.
Jernström H; Department of Clinical Sciences in Lund, Oncology and Pathology, Faculty of Medicine, Lund University Cancer Center / Kamprad, Lund University and Skåne University Hospital, Lund, Sweden. .
Pokaż więcej
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2020 Aug; Vol. 477 (2), pp. 317-320. Date of Electronic Publication: 2020 Feb 20.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor/*genetics
Biomarkers, Tumor/*metabolism
Breast Neoplasms/*pathology
Receptor, ErbB-2/*metabolism
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/metabolism ; Female ; Humans ; Immunohistochemistry/methods ; Middle Aged ; Receptor, ErbB-2/genetics ; Retrospective Studies ; Tissue Array Analysis
Czasopismo naukowe
Tytuł :
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.
Autorzy :
Buqué A; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Bloy N; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Perez-Lanzón M; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Faculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Iribarren K; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Humeau J; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Faculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Pol JG; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Levesque S; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Faculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Mondragon L; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Yamazaki T; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Sato A; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Aranda F; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Durand S; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Boissonnas A; Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses CIMI, Paris, France.
Fucikova J; Sotio, Prague, Czech Republic.; Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
Senovilla L; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
Enot D; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Hensler M; Sotio, Prague, Czech Republic.
Kremer M; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Stoll G; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Hu Y; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA.
Massa C; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Formenti SC; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, New York, NY, USA.
Seliger B; Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Elemento O; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA.; Sandra and Edward Meyer Cancer Center, New York, NY, USA.
Spisek R; Sotio, Prague, Czech Republic.; Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
André F; Gustave Roussy Cancer Center, Villejuif, France.
Zitvogel L; Faculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.; Gustave Roussy Cancer Center, Villejuif, France.; INSERM U1015, Villejuif, France.; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
Delaloge S; Department of Cancer Medicine, Gustave Roussy Cancer Center, Villejuif, France.
Kroemer G; Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. .; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. .; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. .; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China. .; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. .
Galluzzi L; Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. .; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA. .; Sandra and Edward Meyer Cancer Center, New York, NY, USA. .; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA. .; Université de Paris, Paris, France. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Jul 30; Vol. 11 (1), pp. 3819. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Breast Neoplasms/*therapy
Immunotherapy/*methods
Niacinamide/*administration & dosage
Receptor, ErbB-2/*immunology
9,10-Dimethyl-1,2-benzanthracene ; Animals ; Breast Neoplasms/immunology ; Breast Neoplasms/metabolism ; Carcinogenesis/drug effects ; Carcinogenesis/immunology ; Disease Progression ; Female ; Humans ; Interferon Type I/immunology ; Interferon Type I/metabolism ; Mammary Neoplasms, Experimental/chemically induced ; Mammary Neoplasms, Experimental/immunology ; Mammary Neoplasms, Experimental/prevention & control ; Medroxyprogesterone Acetate ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Knockout ; Receptor, ErbB-2/metabolism ; Survival Analysis
Czasopismo naukowe
Tytuł :
Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
Autorzy :
Yamanouchi K; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. .
Kuba S; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Eguchi S; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Pokaż więcej
Źródło :
Surgery today [Surg Today] 2020 Jul; Vol. 50 (7), pp. 657-663. Date of Electronic Publication: 2019 Jun 12.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Axilla*
Lymphatic Metastasis*
Neoplasm Recurrence, Local*
Biomarkers, Tumor/*metabolism
Breast Neoplasms/*diagnosis
Breast Neoplasms/*genetics
Ki-67 Antigen/*metabolism
Receptor, ErbB-2/*metabolism
Receptors, Estrogen/*metabolism
Receptors, Progesterone/*metabolism
Biomarkers, Tumor/genetics ; Breast Neoplasms/pathology ; Female ; Gene Expression ; Humans ; Ki-67 Antigen/genetics ; Prognosis ; Receptor, ErbB-2/genetics ; Receptors, Estrogen/genetics ; Receptors, Progesterone/genetics
Czasopismo naukowe
Tytuł :
ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion.
Autorzy :
Steinhaeuser SS; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Morera E; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Budkova Z; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Schepsky A; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Wang Q; Center for Systems Biology, University of Iceland, Reykjavik, Iceland.
Rolfsson O; Center for Systems Biology, University of Iceland, Reykjavik, Iceland.
Riedel A; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Krueger A; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Hilmarsdottir B; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Maelandsmo GM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Valdimarsdottir B; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Sigurdardottir AK; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Agnarsson BA; Department of Pathology, Landspitali-University Hospital, Reykjavik, Iceland.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Jonasson JG; Department of Pathology, Landspitali-University Hospital, Reykjavik, Iceland.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Ingthorsson S; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Traustadottir GA; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Oskarsson T; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120, Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
Gudjonsson T; Department of Anatomy, Stem Cell Research Unit, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland. .; Center for Systems Biology, University of Iceland, Reykjavik, Iceland. .; Department of Laboratory Hematology, Landspitali-University Hospital, Reykjavik, Iceland. .
Pokaż więcej
Źródło :
Laboratory investigation; a journal of technical methods and pathology [Lab Invest] 2020 Jul; Vol. 100 (7), pp. 928-944. Date of Electronic Publication: 2020 Mar 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms/*metabolism
Extracellular Matrix Proteins/*metabolism
Neoplasm Invasiveness/*genetics
Receptor, ErbB-2/*metabolism
Tumor Microenvironment/*genetics
Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Cell Movement/genetics ; Extracellular Matrix Proteins/genetics ; Female ; Humans ; Receptor, ErbB-2/genetics
Czasopismo naukowe
Tytuł :
Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
Autorzy :
Burguin A; Centre de recherche sur le cancer, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada.; Département de médecine moléculaire, Faculté de médecine, Université Laval, Québec, Canada.
Furrer D; Centre de recherche sur le cancer, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada.; Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, Canada.
Ouellette G; Centre de recherche sur le cancer, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada.; Département de médecine moléculaire, Faculté de médecine, Université Laval, Québec, Canada.
Jacob S; Laboratoire de pathologie, Hôpital du Saint-Sacrement, CHU de Québec-Université Laval, Québec, Canada.; Centre des Maladies du Sein, Hôpital du Saint-Sacrement, Québec, Canada.
Diorio C; Centre de recherche sur le cancer, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada.; Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, Canada.; Centre des Maladies du Sein, Hôpital du Saint-Sacrement, Québec, Canada.
Durocher F; Centre de recherche sur le cancer, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada.; Département de médecine moléculaire, Faculté de médecine, Université Laval, Québec, Canada.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jun 25; Vol. 15 (6), pp. e0234991. Date of Electronic Publication: 2020 Jun 25 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*metabolism
Breast Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Receptor, ErbB-2/*metabolism
Trastuzumab/*pharmacology
Biomarkers, Tumor/antagonists & inhibitors ; Breast/pathology ; Breast Neoplasms/pathology ; Canada ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cohort Studies ; Drug Resistance, Neoplasm ; Female ; Humans ; Phosphorylation ; Protein Kinase Inhibitors/therapeutic use ; Receptor, ErbB-2/antagonists & inhibitors ; Tissue Array Analysis ; Trastuzumab/therapeutic use ; Tyrosine/metabolism
Czasopismo naukowe
Tytuł :
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells.
Autorzy :
DiScala M; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
Najor MS; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
Yung T; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
Morgan D; Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Missouri, United States of America.
Abukhdeir AM; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
Cobleigh MA; Division of Hematology, Oncology, and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jun 11; Vol. 15 (6), pp. e0234146. Date of Electronic Publication: 2020 Jun 11 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents, Immunological/*pharmacology
Drug Resistance, Neoplasm/*drug effects
Receptor, ErbB-2/*metabolism
STAT6 Transcription Factor/*genetics
Trastuzumab/*pharmacology
Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drug Resistance, Neoplasm/genetics ; Epithelial-Mesenchymal Transition ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; RNA, Guide/metabolism ; Receptor, ErbB-2/genetics ; STAT6 Transcription Factor/deficiency
Czasopismo naukowe
Tytuł :
Anti-correlation of HER2 and focal adhesion complexes in the plasma membrane.
Autorzy :
Weinberg F; INM - Leibniz Institute for New Materials, Saarbrücken, Germany.
Han MKL; INM - Leibniz Institute for New Materials, Saarbrücken, Germany.
Dahmke IN; INM - Leibniz Institute for New Materials, Saarbrücken, Germany.
Del Campo A; INM - Leibniz Institute for New Materials, Saarbrücken, Germany.; Department of Chemistry, University of Saarland, Saarbrücken, Germany.
de Jonge N; INM - Leibniz Institute for New Materials, Saarbrücken, Germany.; Department of Physics, University of Saarland, Saarbrücken, Germany.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jun 08; Vol. 15 (6), pp. e0234430. Date of Electronic Publication: 2020 Jun 08 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Spatial Analysis*
Cell Membrane/*metabolism
Focal Adhesions/*metabolism
Receptor, ErbB-2/*metabolism
Cell Adhesion ; Cell Line, Tumor ; Cell Membrane/ultrastructure ; Focal Adhesions/ultrastructure ; Genes, Reporter ; Green Fluorescent Proteins/genetics ; Green Fluorescent Proteins/metabolism ; Humans ; Microscopy, Electron, Scanning Transmission ; Microscopy, Fluorescence ; Receptor, ErbB-2/analysis ; Recombinant Fusion Proteins/analysis ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/metabolism ; Talin/analysis ; Talin/genetics ; Talin/metabolism ; Vinculin/analysis ; Vinculin/genetics ; Vinculin/metabolism
Czasopismo naukowe
Tytuł :
Atypical goblet cell hyperplasia occurs in CPAM 1, 2, and 3, and is a probable precursor lesion for childhood adenocarcinoma.
Autorzy :
Fakler F; Diagnostic and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8036, Graz, Austria.
Aykutlu U; Department of Pathology, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.
Brcic L; Diagnostic and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8036, Graz, Austria.
Eidenhammer S; Diagnostic and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8036, Graz, Austria.
Thueringer A; Diagnostic and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8036, Graz, Austria.
Kashofer K; Diagnostic and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8036, Graz, Austria.
Kulka J; 2nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary.
Timens W; Department of Pathology and Medical Biology, University of Groningen, University Medical Center, Groningen, The Netherlands.
Popper H; Diagnostic and Research Institute of Pathology, Medical University Graz, Neue Stiftingtalstrasse 6, 8036, Graz, Austria. .
Pokaż więcej
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2020 Jun; Vol. 476 (6), pp. 843-854. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma/*pathology
Hyperplasia/*pathology
Receptor, ErbB-2/*metabolism
Adenocarcinoma/congenital ; Adolescent ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Proliferation ; Child ; Child, Preschool ; Female ; Goblet Cells/pathology ; High-Throughput Nucleotide Sequencing ; Humans ; Hyperplasia/congenital ; Infant ; Male ; Receptor, ErbB-2/genetics ; Sequence Analysis, DNA
Czasopismo naukowe
Tytuł :
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Autorzy :
Tolaney SM; Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: .
Wardley AM; The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.
Zambelli S; Istituto Di Ricovero e Cura a Carattere Scientifico, Ospedale San Raffaele, IRCCS, Milano, Italy.
Hilton JF; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada.
Troso-Sandoval TA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ricci F; Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France.
Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Johnston SR; Royal Marsden Hospital, London, UK.
Chan A; Breast Cancer Research Centre-WA, Nedlands, WA, Australia; Curtin University, Nedlands, WA, Australia.
Goel S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
Catron K; Eli Lilly, Indianapolis, IN, USA.
Chapman SC; Eli Lilly, Windlesham, UK.
Price GL; Eli Lilly, Indianapolis, IN, USA.
Yang Z; Eli Lilly, Indianapolis, IN, USA.
Gainford MC; Eli Lilly, Indianapolis, IN, USA.
André F; Gustave Roussy, Université Paris Saclay, INSERM, Villejuif, France.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Jun; Vol. 21 (6), pp. 763-775. Date of Electronic Publication: 2020 Apr 27.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Aminopyridines/*administration & dosage
Antineoplastic Agents, Immunological/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Benzimidazoles/*administration & dosage
Breast Neoplasms/*drug therapy
Estrogen Receptor Antagonists/*administration & dosage
Fulvestrant/*administration & dosage
Receptor, ErbB-2/*antagonists & inhibitors
Receptors, Estrogen/*drug effects
Trastuzumab/*administration & dosage
Aged ; Aminopyridines/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Argentina ; Australia ; Benzimidazoles/adverse effects ; Brazil ; Breast Neoplasms/enzymology ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Disease Progression ; Estrogen Receptor Antagonists/adverse effects ; Europe ; Female ; Fulvestrant/adverse effects ; Humans ; Middle Aged ; North America ; Progression-Free Survival ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Republic of Korea ; Signal Transduction ; Time Factors ; Trastuzumab/adverse effects
Czasopismo naukowe
Tytuł :
Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life.
Autorzy :
Soares LR; Program of Mastology, Federal University of Goiás (UFG), 1ª Avenida, s/n, Setor Universitário, Goiânia, Goiás, CEP: 74.605-020, Brazil.
Rosa VDL; Program of Mastology, Federal University of Goiás (UFG), 1ª Avenida, s/n, Setor Universitário, Goiânia, Goiás, CEP: 74.605-020, Brazil.
Freitas-Junior R; Program of Mastology, Federal University of Goiás (UFG), 1ª Avenida, s/n, Setor Universitário, Goiânia, Goiás, CEP: 74.605-020, Brazil. .
Pokaż więcej
Źródło :
Breast cancer research and treatment [Breast Cancer Res Treat] 2020 Jun; Vol. 181 (3), pp. 693-694. Date of Electronic Publication: 2020 Apr 29.
Typ publikacji :
Letter
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*economics
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*economics
Receptor, ErbB-2/*antagonists & inhibitors
Antibodies, Monoclonal, Humanized/administration & dosage ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Clinical Trials as Topic/economics ; Developing Countries/economics ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis ; Receptor, ErbB-2/metabolism ; Trastuzumab/administration & dosage
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies